Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V.NAMS · Entity 1826 | Chief Accounting Officer | July 20, 2026 | July 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NewAmsterdam Pharma Co N.V.
Report date July 20, 2026 · Filed July 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 24,353 |
Last balance in matching sequence
After 2026-07-20 transaction · row 5
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
5 source rowsRow 1 · 2026-07-20 · Exercise / conversion · Acquired 25,000 · Balance 49,353 F1: Includes 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting. Row 2 · 2026-07-20 · Exercise / conversion · Acquired 80,000 · Balance 129,353 F1: Includes 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting. Row 3 · 2026-07-20 · Sale · Disposed 70,200 · Balance 59,153 F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.57 to $30.56 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. F1: Includes 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting. Row 4 · 2026-07-20 · Sale · Disposed 31,885 · Balance 27,268 F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.58 to $31.57 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. F1: Includes 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting. Row 5 · 2026-07-20 · Sale · Disposed 2,915 · Balance 24,353 F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.58 to $31.85 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. F1: Includes 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.90 · Expires 2033-05-18 | Direct | 10,000 |
Reported balance
After 2026-07-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-07-20 · Exercise / conversion · Disposed 25,000 · Balance 10,000 F5: The option was granted on May 18, 2023. 25% of the shares underlying the option vested on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.17 · Expires 2034-01-01 | Direct | 70,494 |
Reported balance
After 2026-07-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-07-20 · Exercise / conversion · Disposed 80,000 · Balance 70,494 F6: The option was granted on January 1, 2024. 25% of the shares underlying the option vested on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.57 to $30.56 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.58 to $31.57 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.58 to $31.85 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.
F5: The option was granted on May 18, 2023. 25% of the shares underlying the option vested on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
F6: The option was granted on January 1, 2024. 25% of the shares underlying the option vested on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 20, 2026 Filed Jul 22, 2026 20:05 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOption (right to buy) · Derivative | 80,000 | $0.00 Strike: $11.17 | $0.00 |
DisclosureSEC source: 0001193125-26-312387 · ownership.xml · derivative · entry 7 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,494 Underlying: Ordinary Shares · 80,000 shares Expires 2034-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option was granted on January 1, 2024. 25% of the shares underlying the option vested on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. Read SEC document |
| July 20, 2026 Filed Jul 22, 2026 20:05 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOption (right to buy) · Derivative | 25,000 | $0.00 Strike: $11.90 | $0.00 |
DisclosureSEC source: 0001193125-26-312387 · ownership.xml · derivative · entry 6 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,000 Underlying: Ordinary Shares · 25,000 shares Expires 2033-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option was granted on May 18, 2023. 25% of the shares underlying the option vested on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. Read SEC document |
| July 20, 2026 Filed Jul 22, 2026 20:05 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 2,915 | $31.71 | $92,434.65 |
DisclosureSEC source: 0001193125-26-312387 · ownership.xml · nonDerivative · entry 5 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,353 F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.58 to $31.85 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. F1 · balance_after: Includes 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting. Read SEC document |
| July 20, 2026 Filed Jul 22, 2026 20:05 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 31,885 | $31.05 | $990,029.25 |
DisclosureSEC source: 0001193125-26-312387 · ownership.xml · nonDerivative · entry 4 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,268 F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.58 to $31.57 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. F1 · balance_after: Includes 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting. Read SEC document |
| July 20, 2026 Filed Jul 22, 2026 20:05 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 70,200 | $29.96 | $2,103,192.00 |
DisclosureSEC source: 0001193125-26-312387 · ownership.xml · nonDerivative · entry 3 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,153 F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.57 to $30.56 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. F1 · balance_after: Includes 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting. Read SEC document |
| July 20, 2026 Filed Jul 22, 2026 20:05 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOrdinary Shares | 80,000 | $11.17 | $893,600.00 |
DisclosureSEC source: 0001193125-26-312387 · ownership.xml · nonDerivative · entry 2 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 129,353 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting. Read SEC document |
| July 20, 2026 Filed Jul 22, 2026 20:05 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOrdinary Shares | 25,000 | $11.90 | $297,500.00 |
DisclosureSEC source: 0001193125-26-312387 · ownership.xml · nonDerivative · entry 1 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,353 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 20:10 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOption (right to buy) · Derivative | 15,000 | $0.00 Strike: $11.90 | $0.00 |
DisclosureSEC source: 0001193125-26-281062 · ownership.xml · derivative · entry 6 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,000 Underlying: Ordinary Shares · 15,000 shares Expires 2033-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option was granted on May 18, 2023. 25% of the shares underlying the option vest on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 20:10 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOption (right to buy) · Derivative | 25,000 | $0.00 Strike: $10.90 | $0.00 |
DisclosureSEC source: 0001193125-26-281062 · ownership.xml · derivative · entry 5 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,134 Underlying: Ordinary Shares · 25,000 shares Expires 2033-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option was granted on January 1, 2023. 25% of the shares underlying the option vest on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 20:10 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 300 | $30.73 | $9,219.00 |
DisclosureSEC source: 0001193125-26-281062 · ownership.xml · nonDerivative · entry 4 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,353 F2 · balance_after: Includes 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 20:10 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 39,700 | $30.20 | $1,198,940.00 |
DisclosureSEC source: 0001193125-26-281062 · ownership.xml · nonDerivative · entry 3 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,653 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.73 to $30.72 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. F2 · balance_after: Includes 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 20:10 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOrdinary Shares | 15,000 | $11.90 | $178,500.00 |
DisclosureSEC source: 0001193125-26-281062 · ownership.xml · nonDerivative · entry 2 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,353 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 22, 2026 Filed Jun 24, 2026 20:10 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOrdinary Shares | 25,000 | $10.90 | $272,500.00 |
DisclosureSEC source: 0001193125-26-281062 · ownership.xml · nonDerivative · entry 1 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,353 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 26, 2026 Filed May 27, 2026 20:30 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOption (right to buy) · Derivative | 5,000 | $0.00 Strike: $10.90 | $0.00 |
DisclosureSEC source: 0001193125-26-241983 · ownership.xml · derivative · entry 5 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,134 Underlying: Ordinary Shares · 5,000 shares Expires 2033-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option was granted on January 1, 2023. 25% of the shares underlying the option vest on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. Read SEC document |
| May 26, 2026 Filed May 27, 2026 20:30 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOption (right to buy) · Derivative | 60,000 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001193125-26-241983 · ownership.xml · derivative · entry 4 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,015 Underlying: Ordinary Shares · 60,000 shares Expires 2032-11-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option was granted on November 22, 2022. The shares underlying the option vest in equal monthly installments over four years, with the first 1/48th of such shares vesting on December 1, 2022 and the remaining installments vesting on each one-month anniversary of the grant date, subject to the Reporting Person's continued service through each such date. Read SEC document |
| May 26, 2026 Filed May 27, 2026 20:30 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 65,000 | $35.69 | $2,319,850.00 |
DisclosureSEC source: 0001193125-26-241983 · ownership.xml · nonDerivative · entry 3 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,353 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.12 to $36.09 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. F2 · balance_after: Includes 22,000 ordinary shares subject to restricted stock unit awards that remain subject to vesting. Read SEC document |
| May 26, 2026 Filed May 27, 2026 20:30 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOrdinary Shares | 5,000 | $10.90 | $54,500.00 |
DisclosureSEC source: 0001193125-26-241983 · ownership.xml · nonDerivative · entry 2 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,353 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 26, 2026 Filed May 27, 2026 20:30 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOrdinary Shares | 60,000 | $10.00 | $600,000.00 |
DisclosureSEC source: 0001193125-26-241983 · ownership.xml · nonDerivative · entry 1 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 84,353 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 28, 2026 Filed Jan 29, 2026 21:40 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOption (right to buy) · Derivative | 32,612 | $0.00 Strike: $10.90 | $0.00 |
DisclosureSEC source: 0001193125-26-029526 · ownership.xml · derivative · entry 6 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,134 Underlying: Ordinary Shares · 32,612 shares Expires 2033-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option was granted on January 1, 2023. 25% of the shares underlying the option vest on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. Read SEC document |
| January 28, 2026 Filed Jan 29, 2026 21:40 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 32,612 | $31.80 | $1,037,061.60 |
DisclosureSEC source: 0001193125-26-029526 · ownership.xml · nonDerivative · entry 4 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,353 F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.58 to $32.53 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Read SEC document |
| January 28, 2026 Filed Jan 29, 2026 21:40 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOrdinary Shares | 32,612 | $10.90 | $355,470.80 |
DisclosureSEC source: 0001193125-26-029526 · ownership.xml · nonDerivative · entry 3 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,965 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 27, 2026 Filed Jan 29, 2026 21:40 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOption (right to buy) · Derivative | 39,816 | $0.00 Strike: $10.90 | $0.00 |
DisclosureSEC source: 0001193125-26-029526 · ownership.xml · derivative · entry 5 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,746 Underlying: Ordinary Shares · 39,816 shares Expires 2033-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option was granted on January 1, 2023. 25% of the shares underlying the option vest on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. Read SEC document |
| January 27, 2026 Filed Jan 29, 2026 21:40 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 39,816 | $32.62 | $1,298,797.92 |
DisclosureSEC source: 0001193125-26-029526 · ownership.xml · nonDerivative · entry 2 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,353 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.29 to $32.97 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Read SEC document |
| January 27, 2026 Filed Jan 29, 2026 21:40 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOrdinary Shares | 39,816 | $10.90 | $433,994.40 |
DisclosureSEC source: 0001193125-26-029526 · ownership.xml · nonDerivative · entry 1 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,169 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 26, 2026 Filed Jan 27, 2026 22:38 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOption (right to buy) · Derivative | 34,400 | $0.00 Strike: $10.90 | $0.00 |
DisclosureSEC source: 0001193125-26-025012 · ownership.xml · derivative · entry 8 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 145,562 Underlying: Ordinary Shares · 34,400 shares Expires 2033-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option was granted on January 1, 2023. 25% of the shares underlying the option vest on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. Read SEC document |
| January 26, 2026 Filed Jan 27, 2026 22:38 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 309 | $33.45 | $10,336.05 |
DisclosureSEC source: 0001193125-26-025012 · ownership.xml · nonDerivative · entry 6 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,353 F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.40 to $33.51 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Read SEC document |
| January 26, 2026 Filed Jan 27, 2026 22:38 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 34,091 | $32.77 | $1,117,162.07 |
DisclosureSEC source: 0001193125-26-025012 · ownership.xml · nonDerivative · entry 5 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,662 F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.40 to $33.38 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Read SEC document |
| January 26, 2026 Filed Jan 27, 2026 22:38 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOrdinary Shares | 34,400 | $10.90 | $374,960.00 |
DisclosureSEC source: 0001193125-26-025012 · ownership.xml · nonDerivative · entry 4 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,753 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2026 Filed Jan 27, 2026 22:38 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOption (right to buy) · Derivative | 38,172 | $0.00 Strike: $10.90 | $0.00 |
DisclosureSEC source: 0001193125-26-025012 · ownership.xml · derivative · entry 7 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 179,962 Underlying: Ordinary Shares · 38,172 shares Expires 2033-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option was granted on January 1, 2023. 25% of the shares underlying the option vest on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. Read SEC document |
| January 23, 2026 Filed Jan 27, 2026 22:38 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 12,767 | $34.37 | $438,801.79 |
DisclosureSEC source: 0001193125-26-025012 · ownership.xml · nonDerivative · entry 3 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,353 F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.06 to $34.75 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Read SEC document |
| January 23, 2026 Filed Jan 27, 2026 22:38 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 25,405 | $33.44 | $849,543.20 |
DisclosureSEC source: 0001193125-26-025012 · ownership.xml · nonDerivative · entry 2 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,120 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.06 to $34.05 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Read SEC document |
| January 23, 2026 Filed Jan 27, 2026 22:38 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOrdinary Shares | 38,172 | $10.90 | $416,074.80 |
DisclosureSEC source: 0001193125-26-025012 · ownership.xml · nonDerivative · entry 1 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,525 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 07, 2026 Filed Jan 7, 2026 23:27 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | GrantOption (right to buy) · Derivative | 53,500 | $0.00 Strike: $35.45 | $0.00 |
DisclosureSEC source: 0001193125-26-006659 · ownership.xml · derivative · entry 3 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,500 Underlying: Ordinary Shares · 53,500 shares Expires 2036-01-07 F5 · derivative.exercise_date: 25% of the shares underlying the option will vest on Janaury 2, 2027, the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. Read SEC document |
| January 07, 2026 Filed Jan 7, 2026 23:27 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | GrantOrdinary Shares | 12,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-006659 · ownership.xml · nonDerivative · entry 2 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,353 F3 · shares: Represents RSUs, each representing a contingent right to receive one ordinary share. 1/3 of the RSUs will vest on each of the first, second and third anniversaries of the vesting start date, subject to the Reporting Person's continued service through each such date. F4 · price: Each RSU was granted on January 7, 2026 for no consideration. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 23:27 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 2,647 | $33.25 | $88,012.75 |
DisclosureSEC source: 0001193125-26-006659 · ownership.xml · nonDerivative · entry 1 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,353 F1 · kind: Represents pre-arranged sale of shares by the Reporting Person solely to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units (RSUs) pursuant to sell-to-cover agreement entered into with the Issuer. The sale does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.77 to $33.58 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Read SEC document |
| December 26, 2025 Filed Dec 29, 2025 22:14 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOption (right to buy) · Derivative | 5,000 | $0.00 Strike: $10.90 | $0.00 |
DisclosureSEC source: 0001193125-25-335513 · ownership.xml · derivative · entry 11 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 218,134 Underlying: Ordinary Shares · 5,000 shares Expires 2033-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option was granted on January 1, 2023. 25% of the shares underlying the option vest on the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. Read SEC document |
| December 26, 2025 Filed Dec 29, 2025 22:14 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOption (right to buy) · Derivative | 38,872 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001193125-25-335513 · ownership.xml · derivative · entry 10 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,015 Underlying: Ordinary Shares · 38,872 shares Expires 2032-11-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option was granted on November 22, 2022. The shares underlying the option vest in equal monthly installments over four years, with the first 1/48th of such shares vesting on December 1, 2022 and the remaining installments vesting on each one-month anniversary of the grant date, subject to the Reporting Person's continued service through each such date. Read SEC document |
| December 26, 2025 Filed Dec 29, 2025 22:14 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 43,872 | $35.30 | $1,548,681.60 |
DisclosureSEC source: 0001193125-25-335513 · ownership.xml · nonDerivative · entry 7 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,000 F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.85 to $35.56 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Read SEC document |
| December 26, 2025 Filed Dec 29, 2025 22:14 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOrdinary Shares | 5,000 | $10.90 | $54,500.00 |
DisclosureSEC source: 0001193125-25-335513 · ownership.xml · nonDerivative · entry 6 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,872 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 26, 2025 Filed Dec 29, 2025 22:14 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOrdinary Shares | 38,872 | $10.00 | $388,720.00 |
DisclosureSEC source: 0001193125-25-335513 · ownership.xml · nonDerivative · entry 5 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,872 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 24, 2025 Filed Dec 29, 2025 22:14 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOption (right to buy) · Derivative | 26,011 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001193125-25-335513 · ownership.xml · derivative · entry 9 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 178,887 Underlying: Ordinary Shares · 26,011 shares Expires 2032-11-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option was granted on November 22, 2022. The shares underlying the option vest in equal monthly installments over four years, with the first 1/48th of such shares vesting on December 1, 2022 and the remaining installments vesting on each one-month anniversary of the grant date, subject to the Reporting Person's continued service through each such date. Read SEC document |
| December 24, 2025 Filed Dec 29, 2025 22:14 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 26,011 | $35.68 | $928,072.48 |
DisclosureSEC source: 0001193125-25-335513 · ownership.xml · nonDerivative · entry 4 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,000 F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.24 to $36.09 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Read SEC document |
| December 24, 2025 Filed Dec 29, 2025 22:14 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOrdinary Shares | 26,011 | $10.00 | $260,110.00 |
DisclosureSEC source: 0001193125-25-335513 · ownership.xml · nonDerivative · entry 3 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,011 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 23, 2025 Filed Dec 29, 2025 22:14 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOption (right to buy) · Derivative | 75,117 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001193125-25-335513 · ownership.xml · derivative · entry 8 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 204,898 Underlying: Ordinary Shares · 75,117 shares Expires 2032-11-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option was granted on November 22, 2022. The shares underlying the option vest in equal monthly installments over four years, with the first 1/48th of such shares vesting on December 1, 2022 and the remaining installments vesting on each one-month anniversary of the grant date, subject to the Reporting Person's continued service through each such date. Read SEC document |
| December 23, 2025 Filed Dec 29, 2025 22:14 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 75,117 | $36.21 | $2,719,986.57 |
DisclosureSEC source: 0001193125-25-335513 · ownership.xml · nonDerivative · entry 2 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,000 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.88 to $36.75 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Read SEC document |
| December 23, 2025 Filed Dec 29, 2025 22:14 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOrdinary Shares | 75,117 | $10.00 | $751,170.00 |
DisclosureSEC source: 0001193125-25-335513 · ownership.xml · nonDerivative · entry 1 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,117 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 09, 2025 Filed Sep 10, 2025 21:39 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOption (right to buy) · Derivative | 150,000 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0000950170-25-114033 · ownership.xml · derivative · entry 4 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 280,015 Underlying: Ordinary Shares · 150,000 shares Expires 2032-11-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option was granted on November 22, 2022. The shares underlying the option vest in equal monthly installments over four years, with the first 1/48th of such shares vesting on December 1, 2022 and the remaining installments vesting on each one-month anniversary of the grant date, subject to the Reporting Person's continued service through each such date. Read SEC document |
| September 09, 2025 Filed Sep 10, 2025 21:39 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 96,896 | $26.11 | $2,529,954.56 |
DisclosureSEC source: 0000950170-25-114033 · ownership.xml · nonDerivative · entry 3 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.87 to $26.28 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Read SEC document |
| September 09, 2025 Filed Sep 10, 2025 21:39 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | SaleOrdinary Shares | 53,104 | $25.31 | $1,344,062.24 |
DisclosureSEC source: 0000950170-25-114033 · ownership.xml · nonDerivative · entry 2 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,896 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.87 to $25.86 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction. Read SEC document |
| September 09, 2025 Filed Sep 10, 2025 21:39 UTC | NewAmsterdam Pharma Co N.V. NAMS · Entity 1826 | Exercise / conversionOrdinary Shares | 150,000 | $10.00 | $1,500,000.00 |
DisclosureSEC source: 0000950170-25-114033 · ownership.xml · nonDerivative · entry 1 Kooij Louise Frederika · CIK 0002004379 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.